News
In early trading on Monday, shares of biotechnology company GRAIL surged 23% after the company announced a $325 million stock offering to fund its commercial and reimbursement activities. The company expects that this fundraising, along with Samsung's $110 million investment, will support its operations until 2030
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments